← Leaderboards
Ramon Francisco Barajas
Oregon Health & Science University
$2,483,416
Attributed
$2,696,271
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $976.8K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,696,271 · 3
By mechanism
K08$1,180,400 · 1
R37$1,090,160 · 1
R21$425,711 · 1
Top collaborators
- Adem Yildirim2 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Adem Yildirim$875,769
Others in their field
Other Emerging Leaders on “Gadolinium”
- Vera Hoffman · Reveal Pharma$15,740,450
- Mitsue Miyazaki · University Of California, San Diego$6,437,694
- Kim-Lien T Nguyen · Va Greater Los Angeles Healthcare System$4,866,901
- Allison Payne · Utah State Higher Education System--University Of Utah$4,344,898
- Laura J Olivieri · Children'S Research Institute$3,580,980
- Susan A Gauthier · Weill Medical Coll Of Cornell Univ$3,177,857
Research focus
GadoliniumFutureTumorImageMagnetic Resonance ImagingChemoradiationOperative Surgical ProceduresGlioblastomaClinical TrialsInnovationPre-ClinicalMolecular ImagingNanoparticleMonitorMediatingClinicMicrogliaNeuroinflammationImmunotherapeutic AgentDiagnosticImmunosuppressionImmunotherapyIronBiological
Grant awards (9)
Leveraging Biologically Specific PET/MRI Monitoring and Therapeutic Modulation of the Hypoxic Glioblastoma Tumor Immune Microenvironment into Improved Outcomes$542,641
R37 · FY2025 · CA · contact PI
A multifunctional nanomaterial platform for reducing morbidity in medulloblastoma therapy$194,222
R21 · FY2025 · NS
Leveraging Biologically Specific PET/MRI Monitoring and Therapeutic Modulation of the Hypoxic Glioblastoma Tumor Immune Microenvironment into Improved Outcomes$547,519
R37 · FY2024 · CA · contact PI
A multifunctional nanomaterial platform for reducing morbidity in medulloblastoma therapy$231,489
R21 · FY2024 · NS
Defining the Hypoxic Immunosuppressive Microenvironment as a Biomarker of Therapy Efficacy in Glioblastoma Using Iron Oxide Enhanced FMISO PET/MRI$197,748
K08 · FY2024 · CA · contact PI
Defining the Hypoxic Immunosuppressive Microenvironment as a Biomarker of Therapy Efficacy in Glioblastoma Using Iron Oxide Enhanced FMISO PET/MRI$245,663
K08 · FY2023 · CA · contact PI
Defining the Hypoxic Immunosuppressive Microenvironment as a Biomarker of Therapy Efficacy in Glioblastoma Using Iron Oxide Enhanced FMISO PET/MRI$245,663
K08 · FY2022 · CA · contact PI
Defining the Hypoxic Immunosuppressive Microenvironment as a Biomarker of Therapy Efficacy in Glioblastoma Using Iron Oxide Enhanced FMISO PET/MRI$245,663
K08 · FY2021 · CA · contact PI
Defining the Hypoxic Immunosuppressive Microenvironment as a Biomarker of Therapy Efficacy in Glioblastoma Using Iron Oxide Enhanced FMISO PET/MRI$245,663
K08 · FY2020 · CA · contact PI